Specialty drug utilization grows
In 2024, the cost and utilization of specialty dermatology drugs significantly drove a 7% increase in pharmaceutical costs, according to a June 10 report from Navitus Health Solutions, a pharmacy benefits manager. Although specialty medications accounted for less than 2% of utilization, they drove 52% of net pharmaceutical spend in 2024, the report found. Per […]
Metsera’s drug shows potential in early clinical trial – statnews.com
Metsera’s drug shows potential in early clinical trial statnews.com Weight-loss newbie Metsera says once-monthly amylin matches GLP-1 efficacy FirstWord Pharma Obesity Startup Metsera Shares Rise on Early-Stage Trial Results Bloomberg.com Metsera Shares Rise as Monthly Weight Loss Injection Shaves Over 8% Body Weight at 36 Weeks BioSpace Obesity Newcomer Metsera Enters The Ring With A Punch — And A […]
McDonald’s Shares Slump as GLP-1 Risks Spur Rare Sell Rating
McDonald’s Corp. shares slumped on Tuesday after Redburn Atlantic slapped the burger chain with its sole sell rating, saying shifting consumer patterns due to weight-loss drugs and inflation are cause for concern.
PSG Releases 2025 Drug Benefit Design Report: PBM Unbundling Gains Momentum and Payers Navigate GLP-1 Coverage Decisions Amid Rising Costs
DALLAS–(BUSINESS WIRE)–Pharmaceutical Strategies Group (“PSG”), an EPIC company, published its 2025 Trends in Drug Benefit Design Report, delivering critical insights into how payers are navigating a rapidly evolving pharmacy benefits landscape. For three decades, this industry report has been an essential resource for employers, health plans, and other stakeholders seeking to understand and adapt to […]
Lembas GLP-1 Ingredient Manufacturer Enters The Market Following $3.6 Million Pre-Seed Investment
Lembas is a new b2b ingredient business that makes a peptide powder that targets the GLP-1 hormone for weight loss
Who should be taking weight-loss drugs? Doctors share best candidates
Weight-loss drugs continue to grow in popularity, with market researchers predicting that global demand for the medications could reach $150 billion by 2035. GLP-1 agonists — including semaglutides like Ozempic and Wegovy and tirzepatides like Mounjaro and Zepbound — are intended to treat type 2 diabetes and obesity. Recent studies, however, have linked these medications […]
Real-World GLP-1 Weight-Loss Results Differ From Trials
New findings about semaglutide and tirzepatide use from health records suggest lower overall weight loss but also factors that predict success. Medscape Medical News
Injectable medications for obesity found to produce smaller weight loss in a real-world setting
A Cleveland Clinic study shows that semaglutide and tirzepatide—injectable GLP-1 drugs for obesity—produce smaller weight loss in a real-world setting because patients discontinue treatment or use lower maintenance dosages. Treatment discontinuation also negatively impacted blood sugar control in patients with prediabetes. The study was published in the Obesity Journal.
GLP-1 use growing fastest among younger age groups, study finds
A recent study reveals a surge in the use of GLP-1 medications, such as Ozempic and Wegovy, among younger age groups. Originally developed for diabetes, these drugs are now popular for weight loss, especially following expanded approval for adolescents.
STAT+: National Resilience, startup hoping to reinvent drug manufacturing, to ‘wind down’ many of its facilities
National Resilience, a startup that has raised over $2 billion by promising to transform drug manufacturing, said Monday that it would “wind down” many of its facilities. But what remains of the firm has raised an additional $250 million from existing investors to continue to build its business and seek more capital. Through a bit […]